No connection

Search Results

BNGO vs SINT

BNGO
Bionano Genomics, Inc.
BEARISH
Price
$1.15
Market Cap
$11.7M
Sector
Healthcare
AI Confidence
85%
SINT
Sintx Technologies, Inc.
BEARISH
Price
$2.69
Market Cap
$11.1M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
BNGO
--
SINT
--
Forward P/E
BNGO
-0.46
SINT
-1.53
P/B Ratio
BNGO
0.22
SINT
3.64
P/S Ratio
BNGO
0.39
SINT
10.89
EV/EBITDA
BNGO
-0.45
SINT
-1.0

Profitability

Gross Margin
BNGO
45.97%
SINT
45.28%
Operating Margin
BNGO
-115.89%
SINT
-787.59%
Profit Margin
BNGO
-134.36%
SINT
0.0%
ROE
BNGO
-78.22%
SINT
-303.8%
ROA
BNGO
-19.31%
SINT
-69.8%

Growth

Revenue Growth
BNGO
21.3%
SINT
-46.5%
Earnings Growth
BNGO
--
SINT
--

Financial Health

Debt/Equity
BNGO
0.35
SINT
1.11
Current Ratio
BNGO
2.12
SINT
1.51
Quick Ratio
BNGO
1.14
SINT
1.16

Dividends

Dividend Yield
BNGO
--
SINT
--
Payout Ratio
BNGO
0.0%
SINT
0.0%

AI Verdict

BNGO BEARISH

BNGO exhibits severe financial distress despite modest revenue growth, as reflected in its Piotroski F-Score of 1/9—indicating weak operational and financial health. The absence of an Altman Z-Score and the company's negative profitability metrics (e.g., -134.36% profit margin, -78.22% ROE) signal deep operational inefficiencies and high risk of insolvency. Although the stock shows a recent technical uptick and strong earnings surprise history, these are overshadowed by deteriorating fundamentals, massive losses, and a 5-year price decline of 100%. The lack of a Graham Number and intrinsic value estimate further underscores the absence of a reliable valuation anchor. Analysts have a target price of $5.50, but this is not supported by current fundamentals and appears speculative.

Strengths
21.30% year-over-year revenue growth indicates market traction in a high-growth sector
Gross margin of 45.97% suggests strong pricing power and cost control in product delivery
Recent quarterly earnings surprises (average +42.66%) show potential for better-than-expected execution
Risks
Piotroski F-Score of 1/9 is critically low, signaling severe financial deterioration and poor operational efficiency
Negative ROE (-78.22%) and ROA (-19.31%) reflect deep capital inefficiency and sustained losses
Profit margin of -134.36% and operating margin of -115.89% indicate unsustainable business model at current scale
SINT BEARISH

SINT exhibits severe financial distress, anchored by a critical Piotroski F-Score of 1/9 and a catastrophic operating margin of -787.59%. The company is experiencing a collapse in its top line with YoY revenue growth at -46.50% and a consistent track record of missing earnings estimates (0/4 beats in the last year). Despite a 'Strong Buy' analyst consensus and a target price of $10.17, the fundamental data suggests a company in a death spiral with a 5-year price change of -100%. The disconnect between analyst optimism and the deterministic health scores indicates extreme speculative risk.

Strengths
Positive Gross Margin (45.28%) suggesting some product-level viability
Current Ratio of 1.51 provides a minimal short-term liquidity buffer
Quick Ratio of 1.16 indicates ability to cover immediate liabilities
Risks
Severe revenue contraction (-46.50% YoY)
Extreme operational inefficiency (Operating Margin -787.59%)
Massive equity erosion (ROE -303.80%)

Compare Another Pair

BNGO vs SINT: Head-to-Head Comparison

This page compares Bionano Genomics, Inc. (BNGO) and Sintx Technologies, Inc. (SINT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile